Clinical Trials Logo

Clinical Trial Summary

Treatment of patients with febrile neutropenia (FN) attending Emergency Departments (EDs) relies on rapid antibiotic initiation in order to control a presumed infection. The choice of initial antibiotics is empirical and depends on patient's prior colonization or infection by multi-drug resistant pathogens (MDRPs) and risk stratification. Stratification of high-risk patients needing broad-spectrum antibiotics is debated. Thus, for non-specialist physicians, this choice may be challenging, leading to inappropriate initial antimicrobial regimens, potential risks for the patient and higher costs. Furthermore, international guidelines recommended to develop antibiotic stewardship programs and promoted an initial strategy based on escalation or de-escalation approaches, with early reassessment depending on patients' clinical course and microbiological results. Nevertheless, this interesting strategy may increase the level of complexity for the choice of the initial antibiotic regimen by non-specialist emergency physicians who are often the first prescribers in this context. We developed an interactive computerized decision support app (CDSA) for initial antibiotic prescription and early revaluation in patients with FN. The first goal of this app is to assist non-specialized physicians in choosing initial antimicrobial regimen for patients with FN when they attend EDs. It uses an interactive algorithm based on international guidelines that takes into account patients' medical history and characteristics. Secondly, the app is also designed to propose an algorithm of antibiotic revaluation at day 3-4 for hospitalized patients, depending on patient clinical course, and biological and microbiological results. The revaluation suggests antimicrobial modification (escalation or de-escalation) or discontinuation and stopping rules with recommended duration of therapy also based on international guidelines. We hypothesize that such a CDSA may improve the adherence to guidelines for the choice of initial antibiotic regimen for FN in the ED, favour early antibiotic reassessment for hospitalized patients, both decreasing the risk of treatment failure.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05206006
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Olivier Peyrony
Phone +33142494804
Email olivier.peyrony@aphp.fr
Status Not yet recruiting
Phase N/A
Start date February 14, 2022
Completion date June 21, 2023

See also
  Status Clinical Trial Phase
Completed NCT03641131 - Ampholipad Real-World Data in Taiwan
Not yet recruiting NCT02806557 - Profiling Neutrophil Counts in Patients on Chemotherapy N/A
Completed NCT04914702 - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Completed NCT02728596 - S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) N/A
Completed NCT03104595 - Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer Phase 1/Phase 2
Recruiting NCT02536599 - Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & Neutropenia
Completed NCT02005783 - Study of Danggui Buxue Decoction in Preventing Neutropenia Phase 2
Recruiting NCT03449693 - Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia Phase 2
Recruiting NCT05149547 - mNGS Versus Blood Culture in FN
Recruiting NCT05584930 - Clusterin, Ptx3 and Pediatric Febrile Neutropenia (CluPPFeN) N/A
Completed NCT04134429 - Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
Recruiting NCT01684189 - Registry of Febrile Neutropenia and Invasive Fungal Infections N/A
Completed NCT00462878 - Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation N/A
Completed NCT00035425 - Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection Phase 3
Recruiting NCT04948463 - Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia Phase 4
Recruiting NCT03740464 - Long-acting G-CSF for Febrile Neutropenia Phase 3
Not yet recruiting NCT06116734 - Lapelga vs Gastrofil Phase 3
Completed NCT00503854 - Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
Terminated NCT02732327 - Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer Phase 2
Completed NCT01114165 - Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients Phase 4